Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

December 12, 2025

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

December 11, 2025

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

December 9, 2025

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

December 4, 2025

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

November 26, 2025

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

November 14, 2025

Enveric Biosciences Announces Reverse Stock Split

October 23, 2025

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

October 16, 2025

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

October 15, 2025

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

October 14, 2025

1
2
3
…
18
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2025 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.